{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:19:18Z","timestamp":1759709958682,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ctrv.2022.102357","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T02:10:48Z","timestamp":1644459048000},"page":"102357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients"],"prefix":"10.1016","volume":"104","author":[{"given":"Marina","family":"Macchini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Peretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Militello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Maddalena","family":"Valente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Cascinu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Reni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2022.102357_b0005","first-page":"7","article-title":"Cancer Statistic, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2022.102357_b0010","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of tyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102357_b0015","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/1055-9965.EPI-18-1235","article-title":"Analysis of heritability and genetic architecture of pancreatic cancer: a PanC4 study","volume":"28","author":"Chen","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102357_b0020","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1053\/j.seminoncol.2016.09.002","article-title":"Familial pancreatic cancer","volume":"43","author":"Petersen","year":"2016","journal-title":"Semin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102357_b0025","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nature Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2022.102357_b0030","doi-asserted-by":"crossref","first-page":"102262","DOI":"10.1016\/j.ctrv.2021.102262","article-title":"Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants","volume":"100","author":"Macchini","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102357_b0035","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2022.102357_b0040","doi-asserted-by":"crossref","first-page":"101895","DOI":"10.1016\/j.ctrv.2019.101895","article-title":"Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis","volume":"80","author":"Rebelatto","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102357_b0045","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl Med"},{"key":"10.1016\/j.ctrv.2022.102357_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100238","article-title":"Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCa1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey","volume":"6","author":"Orsi","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2022.102357_b0055","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.2147\/CMAR.S211151","article-title":"BRCA mutations in Pancreas Cancer: Spectrum, current management, challenges and future prospects","volume":"12","author":"Wong","year":"2020","journal-title":"Cancer Manage Res"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102357_b0060","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1055-9965.EPI-06-0783","article-title":"The prevalence of BRCA2 mutations in familial pancreatic cancer","volume":"16","author":"Couch","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ctrv.2022.102357_b0065","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.19.01890","article-title":"Geographic and ethnic heterogeneity of germline BRCa1 or BRCA2 mutation prevalence amomg patients with metastatic pancreatic cancer screened for entry into the POLO trial","volume":"38","author":"Golan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102357_b0070","doi-asserted-by":"crossref","first-page":"100032","DOI":"10.1016\/j.esmoop.2020.100032","article-title":"Germinal BRCA1-2 pathogenic variants (gBRCA1-2 pv) and pancreatic cancer: epidemiology of an Italian patient cohort","volume":"6","author":"Peretti","year":"2021","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.ctrv.2022.102357_b0075","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1002\/cncr.33038","article-title":"Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma","volume":"126","author":"McIntyre","year":"2020","journal-title":"Cancer"},{"issue":"30","key":"10.1016\/j.ctrv.2022.102357_b0080","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102357_b0085","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jamcollsurg.2017.12.021","article-title":"BRCA1\/2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma","volume":"226","author":"Blair","year":"2018","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102357_b0090","doi-asserted-by":"crossref","first-page":"e000578","DOI":"10.1136\/esmoopen-2019-000578","article-title":"Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies","volume":"5","author":"Pokataev","year":"2020","journal-title":"ESMO Open"},{"issue":"24","key":"10.1016\/j.ctrv.2022.102357_b0095","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1002\/cncr.29664","article-title":"Identification of germline genetic mutations in patients with pancreatic cancer","volume":"121","author":"Salo-Mullen","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102357_b0100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1006\/gyno.2000.5848","article-title":"Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients","volume":"78","author":"Tobias","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2022.102357_b0105","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/1940-6207.CAPR-18-0014","article-title":"High prevalence of hereditary cancer syndromes and outcomes in adult with early-onset pancreatic cancer","volume":"11","author":"Bannon","year":"2018","journal-title":"Cancer Prev Res"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102357_b0110","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102357_b0115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1158\/1055-9965.EPI-15-0455","article-title":"Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients","volume":"25","author":"Hu","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102357_b0120","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/gim.2014.153","article-title":"BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study","volume":"17","author":"Zhen","year":"2015","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102357_b0125","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","article-title":"Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer","volume":"148","author":"Grant","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102357_b0130","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4573-5","article-title":"Pancreatic cancer as a sentinel for hereditary cancer predisposition","volume":"18","author":"Young","year":"2018","journal-title":"BMC Cancer"},{"issue":"45","key":"10.1016\/j.ctrv.2022.102357_b0135","doi-asserted-by":"crossref","first-page":"74227","DOI":"10.18632\/oncotarget.12490","article-title":"Germline mutations in Japanese familial pancreatic cancer patients","volume":"7","author":"Takai","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102357_b0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-26526-x","article-title":"Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma","volume":"8","author":"Takeuchi","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102357_b0145","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10637-017-0497-1","article-title":"Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing","volume":"36","author":"Lee","year":"2018","journal-title":"Invest New Drug"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102357_b0150","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.01.220","article-title":"Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma","volume":"160","author":"Golan","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102357_b0155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","article-title":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","volume":"21","author":"Yurgelun","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.ctrv.2022.102357_b0160","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.20.03238","article-title":"Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence mate-analysis","volume":"39","author":"Casolino","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102357_b0165","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1053\/j.gastro.2019.01.254","article-title":"Prevalence of germline mutations associated with cancer risk in patients with intraductal papillary mucinous neoplasm","volume":"156","author":"Skaro","year":"2019","journal-title":"Gastroenterology"},{"issue":"5924","key":"10.1016\/j.ctrv.2022.102357_b0170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1171202","article-title":"Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene","volume":"324","author":"Jones","year":"2009","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102357_b0175","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"3_suppl","key":"10.1016\/j.ctrv.2022.102357_b0180","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1200\/JCO.2021.39.3_suppl.396","article-title":"Genomic characterization of ATM alterations in advanced pancreatic ductal adenocarcinoma (PDAC)","volume":"39","author":"Perera","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102357_b0185","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"issue":"24","key":"10.1016\/j.ctrv.2022.102357_b0190","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1158\/1078-0432.CCR-20-1788","article-title":"Effect of germline mutations in homologous recombination repair genes on overall survival of patients with pancreatic adenocarcinoma","volume":"26","author":"Yadav","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102357_b0195","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/clpt.2008.144","article-title":"Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice","volume":"84","author":"Huang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"15","key":"10.1016\/j.ctrv.2022.102357_b0200","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-09-0344","article-title":"Cancer Pharmacoethnicity: Ethnic differences in susceptibility to the effects of chemotherapy","volume":"15","author":"O'Donnell","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102357_b0205","article-title":"Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2022.102357_b0210","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O'Reilly","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102357_b0215","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1200\/JCO.2009.25.4433","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study","volume":"28","author":"Colucci","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102357_b0220","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2468-1253(18)30196-1","article-title":"Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomized phase 2 trial","volume":"3","author":"Reni","year":"2018","journal-title":"Lancet Gastroenterol Hepathol"},{"key":"10.1016\/j.ctrv.2022.102357_b0225","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Eng J Med"},{"issue":"18","key":"10.1016\/j.ctrv.2022.102357_b0230","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Eng J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102357_b0235","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/igc.0000000000001144","article-title":"BRCA mutation status is not associated with increased hematologic toxicity among patients undergoing platinum-based chemotherapy for ovarian cancer","volume":"28","author":"Kotsopoulos","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ctrv.2022.102357_b0240","doi-asserted-by":"crossref","first-page":"e1471","DOI":"10.1634\/theoncologist.2019-0272","article-title":"Chemotherapy toxicity in BRCA mutation carriers undergoing first-line platinum-based chemotherapy","volume":"24","author":"Weitzner","year":"2019","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102357_b0245","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1002\/cam4.2471","article-title":"Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: a retrospective matched cohort study","volume":"8","author":"West","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2022.102357_b0250","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000354834","article-title":"The influence of BRCA1\/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients","volume":"85","author":"Huszno","year":"2013","journal-title":"Oncology"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:27:49Z","timestamp":1759656469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222000202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":50,"alternative-id":["S0305737222000202"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102357","relation":{},"ISSN":["0305-7372"],"issn-type":[{"type":"print","value":"0305-7372"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102357"}}